A hitherto unreported impurity in Terazosin – elucidation of the structure, synthesis and cytotoxicity
DOI:
https://doi.org/10.13171/mjc10502005171436rcAbstract
Analysis of several batches of the a1–adrenergic blocking agent terazosin being used as a medication for treating benign prostatic hyperplasia and hypertension revealed the presence of a hitherto not reported impurity. The latter was isolated, and its structure was elucidated from NMR and Mass Spectrometry (MS) data and unambiguously confirmed by independent synthesis. This contamination, represented in 1-[4-(amino-6,7-dimethoxyquinazolin-2-yl)-piperazin-1-yl]-pentane-1,2-dione 2 is likely to occur as the product of a side-reaction in the catalytic hydrogenation step during the synthesis of the drug. Biological screening showed this compound as not cytotoxic for several human tumor cell lines and non-malignant fibroblasts.
References
- S.B. Bari, P.S. Jain, A.A. Shirkhedkar, L.V. Sonawane, A.J. Mhaske, J.B. Gawad, Impurities in pharmaceuticals: a review, World J. Pharm. Res., 2015, 4, 2932-2947.
- C.M. Callis, J.P. Bercu, K.M. DeVries, L.K. Dow, D.K. Robbins, D.L. Varie, Risk Assessment of Genotoxic Impurities in Marketed Compounds Administered over a Short-Term Duration: Applications to Oncology Products and Implications for Impurity Control Limits, Org. Process Res. Dev., 2010, 14, 986-992.
- M. Honma, Thresholds of toxicological concern for genotoxic impurities in pharmaceuticals, in: F. Nohmi, S. Fukushima (Eds.) Thresholds of genotoxic carcinogens: From mechanisms to regulation, Academic Press, Amsterdam, 2016, 103-115.
- S. Schmidtsdorff, A.H. Schmidt, Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography, J. Pharm. Biomed. Anal., 2019, 174, 151-160.
- M. Batty, R. Pugh, I. Rathinam, J. Simmonds, E. Walker, A. Forbes, S. Anoopkumar-Dukie, C.M. McDermott, B. Spencer, D. Christie, R. Chess-Williams, The role of α1-adrenoceptor antagonists in the treatment of prostate and other cancers, Int. J. Mol. Sci., 2016, 17, 1339.
- M. Oelke, A. Gericke, M.C. Michel, Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms, Expert Opin. Drug Saf., 2014, 13, 1187-1197.
- A. Wadhawan, A. Banga, Y. Duan, M. Mennesson, Z.H. Wu, Alpha1-Adrenergic Receptor Antagonists Use in Treatment and Prevention of Psychiatric Disorders: A Review, Curr. Psychopharmacol., 2014, 3, 158-183.
- H. Wood, Could a prostate drug be repurposed for Parkinson disease? Nat. Rev. Neurol., 2019, 15, 621.
- J.Q. Yuan, Y. Liu, Z.Y. Yang, X. Qin, K.H. Yang, C. Mao, The efficacy and safety of alpha- 1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews, Curr. Med. Res. Opin., 2013, 29, 279-287.
- U. Dunzendorfer, Clinical experience: symptomatic management of BPH with Terazosin, Urology, 1988, 32, 27-31.
- H. Lepor, M. Baumann, E. Shapiro, The alpha-adrenergic binding properties of Terazosin in the human prostate adenoma and canine brain, J. Urol. (Baltimore), 1988, 140, 664-667.
- H. Lepor, D.I. Gup, M. Baumann, E. Shapiro, Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia, Urology, 1988, 32, 21-26.
- P.M. Parker, The 2019-2024 World Outlook for Pulmonary arterial hypertension (PAH) Therapeutics, Icon Group International, Las Vegas, 2018.
- A.F. Fliri, W.T. Loging, R.A. Volkmann, Drug effects viewed from a signal transduction network perspective, J. Med. Chem., 2009, 52, 8038-8046.
- A. Ghaleiha, K.M. Shahidi, S. Afzali, N. Matinnia, Effect of Terazosin on sweating in patients with major depressive disorder receiving sertraline: A randomized controlled trial, Int. J. Psychiatry Clin. Pract., 2013, 17, 44-47.
- R. Mago, M.E. Thase, B.W. Rovner, Antidepressant-induced excessive sweating: clinical features and treatment with Terazosin, Ann Clin Psychiatry, 2013, 25, 186-192.
- https.//www.parkinson-gesellschaft.de; last accessed 2020-01-22.
- R. Cai, Y. Yuan, Z. Chen, Y. Han, X. Ji, R. Cai, Y. Li, W. Su, L. Gao, X. Ji, L. Liu, Y. Zhang, J.E. Simmering, J.L. Schultz, I. Fernandez-Carasa, A. Consiglio, A. Consiglio, A. Raya, A. Raya, P.M. Polgreen, N.S. Narayanan, C. Zhao, L. Liu, M.J. Welsh, Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases, J. Clin. Invest., 2019, 129, 4539-4549.
- J. Xia, B. Feng, Q. Shao, Y. Yuan, W.X. Simon, N. Chen, S. Wu, Virtual screening against phosphoglycerate kinase 1 in quest of novel apoptosis inhibitors, Molecules, 2017, 22, 1029.
- A. Cavalli, F. Lizzi, S. Bongarzone, R. Brun, R. Luise Krauth-Siegel, M.L. Bolognesi, Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase, Bioorg. Med. Chem. Lett., 2009, 19, 3031-3035.
- Z. Ma, Y. Lin, Y. Cheng, W. Wu, R. Cai, S. Chen, B. Shi, B. Han, X. Shi, Y. Zhou, L. Du, M. Li, Discovery of the First Environment-Sensitive Near-Infrared (NIR) Fluorogenic Ligand for α1-Adrenergic Receptors Imaging in Vivo, J. Med. Chem., 2016, 59, 2151-2162.
- Z. Ma, Z. Liu, T. Jiang, T. Zhang, H. Zhang, L. Du, M. Li, Discovery of Fluorescence Polarization Probe for the ELISA-Based Antagonist Screening of α1-Adrenergic Receptors, ACS Med. Chem. Lett., 2016, 7, 967-971.
- A. Petty, N. Idippily, V. Bobba, W.J. Geldenhuys, B. Zhong, B. Su, B. Wang, Design and synthesis of small molecule agonists of EphA2 receptor, Eur. J. Med. Chem., 2018, 143, 1261-1276.
- T. Sekiya, H. Hiranuma, S. Hata, S. Mizogami, M. Hanazuka, S. Yamada, Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives, J. Med. Chem., 1983, 26, 411-416.
- A. Bottini, S.K. De, B. Wu, C. Tang, G. Varani, M. Pellecchia, Targeting Influenza A Virus RNA Promoter, Chem. Biol. Drug Des., 2015, 86, 663-673.
- N.S. Date, V. La Parola, C.V. Rode, M.L. Testa, Ti-doped Pd-Au catalysts for one-pot hydrogenation and ring-opening of furfural, Catalysts, 2018, 8, 252.
- S. Mitsui, Y. Ishikawa, Y. Takeuchi, Hydrogenation end decomposition. 14. Part Catalytic reduction of the furan derivatives with Palladium-und Raney-Nickel-Katalysator, Chem. Zentralbl., 1965, 136, 16538.
- I.F. Bel’skii, N.I. Shuikin, Catalytic hydrogenation and hydrogenolysis of furan compounds, Usp. Khim., 1963, 32, 707-736.
- N.I. Shuikin, R.A. Karakhanov, I. Ibrakhimov, Conversion of tetrahydrofuran homologs over palladized carbon, Izv. Akad. Nauk SSSR Ser. Khim., 1965, 1, 165-167.
- S. Wang, V. Vorotnikov, D.G. Vlachos, A DFT study of furan hydrogenation and ring-opening on Pd(111), Green Chem. 2014, 16, 736-747.
- N.I. Shuikin, I.F. Bel’skii, Hydrogenation of furan compounds over nickel catalysts, Zh. Obshch. Khim., 1959, 29, 3627-3631.
- T. Mizugaki, T. Yamakawa, Y. Nagatsu, Z. Maeno, T. Mitsudome, K. Jitsukawa, K. Kaneda, Direct transformation of furfural to 1,2-pentanediol using a hydrotalcite-supported platinum nanoparticle catalyst, ACS Sustain. Chem. Engin., 2014, 2, 2243-2247.
- M. Kahnt, J. Wiemann, L. Fischer, S. Sommerwerk, R. Csuk, Transformation of asiatic acid into a mitocanic, bimodal-acting rhodamine B conjugate of anomolar cytotoxicity, Eur. J. Med. Chem., 2018, 159, 143-148.
- N. Kyprianou, C.M. Benning, Suppression of human prostate cancer cell growth by a 1-adrenoceptor antagonists doxazosin and Terazosin via induction of apoptosis, Cancer Res., 2000, 16, 4550-4555.
Downloads
Additional Files
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).